Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 65Neoplasm Metastasis 56Leukemia, Myeloid, Acute 55Multiple Myeloma 44Prostatic Neoplasms 43Melanoma 43Lung Neoplasms 39Colorectal Neoplasms 36Lymphoma 33Pancreatic Neoplasms 31Leukemia, Lymphocytic, Chronic, B-Cell 30Carcinoma, Non-Small-Cell Lung 29Myelodysplastic Syndromes 26Squamous Cell Carcinoma of Head and Neck 25Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 22Neoplasms 22Ovarian Neoplasms 21Burkitt Lymphoma 21Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Sarcoma 17Lymphoma, Mantle-Cell 17Glioma 17Uterine Cervical Neoplasms 16Rectal Neoplasms 16Leukemia, Myelomonocytic, Chronic 15Fallopian Tube Neoplasms 15Stomach Neoplasms 14

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2capmatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms by Histologic Type × Biopsy × Clear all
NCT07416188 2026-06-05

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
40 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡